Pain treatment biotech Egalet sets terms for $42 million IPO

Comment

Shutterstock photo

Egalet, which is developing abuse-deterrent oral products for the treatment of pain, announced terms for its IPO on Thursday. The Malvern, PA-based company plans to raise $42 million by offering 3.5 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Egalet would command a market value of $167 million.

Egalet, which was founded in 1995, plans to list on the NASDAQ under the symbol EGLT. Egalet initially filed confidentially on September 17, 2013. Stifel and JMP Securities are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com